Zurück

Wählen Sie Ihre Region

Corporate

Europa:

Flagge Albanien Albanien Flagge Bosnien-Herzegowina Bosnien-Herzegowina Flagge Bulgarien Bulgarien Flagge Kroatien Kroatien Flagge Zypern Zypern Flagge Montenegro Montenegro Flagge Tschechien Tschechien Flagge Dänemark Dänemark Flagge Estland Estland Flagge Spanien Spanien Flagge Kosovo Kosovo Flagge Litauen Litauen Flagge Lettland Lettland Flagge Luxemburg Luxemburg Flagge Mazedonien Mazedonien Flagge Deutschland Deutschland Flagge Polen Polen Flagge Portugal Portugal Flagge Rumänien Rumänien Flagge Serbien Serbien Flagge Slowakei Slowakei Flagge Slowenien Slowenien Flagge Schweiz Schweiz Flagge Schweden Schweden Flagge Türkei Türkei Flagge Ungarn Ungarn Flagge Großbritannien Großbritannien Flagge Italien Italien

Asien:

Flagge UAE UAE Flagge Hong Kong Hong Kong Flagge Kuwait Kuwait Flagge Libanon Libanon

Afrika:

Flagge Südafrika Südafrika

Vereinbaren Sie ein Beratungsgespräch über Stammzellen

Mehr erfahren

Kontaktieren Sie uns noch heute!

Möchten Sie mehr über unsere Dienstleistungen erfahren? Füllen Sie das untenstehende Formular aus, und wir werden uns so schnell wie möglich mit Ihnen in Verbindung setzen, um Ihnen alle notwendigen Informationen zu geben und Ihre Fragen zu beantworten.

    Wir möchten Sie darauf hinweisen, dass die im Formular angegebenen personenbezogenen Daten von FamiCord Suisse mit Sitz in der Schweiz (BusinessPark Zug Sumpfstrasse 26, 6302 Zug) zur telefonischen Kontaktaufnahme im Zusammenhang mit der Erteilung von Serviceinformationen verarbeitet werden.

    Obraz

    Unsere
    Transplantationen

    Liste der Verwendungen von Stammzellen, die von den Laboren der FamiCord-Gruppe freigegeben wurden:

    Obraz
    Liste der Verwendungen von Stammzellen, die von den Laboren der FamiCord-Gruppe freigegeben wurden:
    Nr. Quelle Quellentyp Diagnose Medizinbereich Anwendungsjahr Therapie Land Alter des Empfängers
    401 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 42
    402 Apheresis allogeneic MPS-I: Hurler Syndrome Hematology 2026 Standard Therapy Russia 1
    403 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 29
    404 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 47
    405 Apheresis allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 66
    406 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 4
    407 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
    408 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 63
    409 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Lithuania 40
    410 Apheresis allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 68
    411 Apheresis allogeneic Chronic Lymphocytic Leukemia Hematology 2026 Standard Therapy Netherlands 61
    412 Apheresis allogeneic Acute Lymphoblastic leukemia Hematology 2026 Standard Therapy Germany 21
    413 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 72
    414 Apheresis allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 36
    415 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 57
    416 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Belgium 63
    417 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy United Kingdom 54
    418 Apheresis allogeneic Other Malignancy, Specify Hematology 2026 Standard Therapy USA 54
    419 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 76
    420 Apheresis allogeneic Myelodysplastic Disorders Hematology 2026 Standard Therapy France 73
    421 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 75
    422 Apheresis allogeneic Hodgkin Lymphoma Hematology 2026 Standard Therapy Poland 47
    423 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 68
    424 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 40
    425 Apheresis allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Macedonia 59
    426 Apheresis allogeneic Combined Immunodeficiency Hematology 2026 Standard Therapy Belgium 4
    427 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Australia 13
    428 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 33
    429 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 38
    430 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Russian Federation 28
    431 Apheresis allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Germany 58
    432 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Austria 54
    433 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 74
    434 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy United Kingdom 20
    435 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 57
    436 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 69
    437 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 64
    438 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 56
    439 Apheresis autologous Myeloma Hematology 2026 Standard Therapy Portugal 42
    440 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 56
    441 Apheresis Autologous T-Cell Lymphoma Hematology 2026 Standard Therapy Germany 68
    442 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 71
    443 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
    444 Apheresis Allogeneic T-Cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 24
    445 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 67
    446 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 62
    447 Apheresis Autologous Plasma Cell Leukemia Hematology 2026 Standard Therapy Germany 43
    448 Apheresis Autologous Mantle Cell Lymphoma Hematology 2026 Standard Therapy Germany 60
    449 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 68
    450 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 68
    451 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 70
    452 Apheresis Allogeneic Primary Myelopathic Polycythemia Hematology 2026 Standard Therapy Germany 67
    453 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
    454 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 56
    455 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 69
    456 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Portugal 32
    457 Apheresis Autologous Lymphoma Hematology 2026 Standard Therapy Portugal 64
    458 Apheresis Autologous Lymphoma Hematology 2026 Standard Therapy Portugal 64
    459 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 42
    460 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 65
    461 Apheresis Allogeneic Chronic myelomonocytic leukemia Hematology 2026 Standard Therapy Germany 73
    462 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 63
    463 Apheresis Allogeneic Thalassemia Major Hematology 2026 Standard Therapy Italy 6
    464 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 63
    465 Apheresis Allogeneic Hemophagocytic Lymphohistiocytosis Hematology 2026 Standard Therapy India 3
    466 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Bulgaria 32
    467 Apheresis Allogeneic Mixed-Phenotype Acute Leukemia Hematology 2026 Standard Therapy Poland 40
    468 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 64
    469 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Ukraine 58
    470 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 62
    471 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 45
    472 Apheresis Allogeneic T-cell non-Hodgkin Lymphoma (Mycosis Fungoides) Hematology 2026 Standard Therapy Portugal 43
    473 Apheresis Allogeneic Plasma Cell Leukemia Hematology 2026 Standard Therapy Germany 62
    474 Apheresis Allogeneic Hodgkin’s Disease Hematology 2026 Standard Therapy Italy 34
    475 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy France 20
    476 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 40
    477 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 51
    478 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 58
    479 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Ukraine 45
    480 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Ukraine 41
    481 Apheresis Allogeneic Hodgkin's Disease Hematology 2026 Standard Therapy Poland 44
    482 Apheresis Allogeneic Multiple Myeloma Hematology 2026 Standard Therapy USA 47
    483 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Colombia 57
    484 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Australia 72
    485 Apheresis Allogeneic EBV-positive nodal T- and NK-cell lymphoma Hematology 2026 Standard Therapy Poland 68
    486 Apheresis Allogeneic Acute Myeloid Leukemia, Myelodysplasia-Related Hematology 2026 Standard Therapy Russia Federation 48
    487 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Finland 69
    488 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 67
    489 Apheresis Allogeneic Large Cell Anaplastic Lyphoma ALK Hematology 2026 Standard Therapy Serbia 13
    490 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 74
    491 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Lithuania 64
    492 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 67
    493 Apheresis Allogeneic Acute Undifferentiated Leukemia Hematology 2026 Standard Therapy USA 16
    494 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Czechia 53
    495 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
    496 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy India 18
    497 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 50
    498 Apheresis Allogeneic Chronic myelomonocytic leukemia Hematology 2026 Standard Therapy Lithuania 66
    499 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 51
    500 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 41